AR013498A1 - Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa - Google Patents
Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfaInfo
- Publication number
- AR013498A1 AR013498A1 ARP980104605A ARP980104605A AR013498A1 AR 013498 A1 AR013498 A1 AR 013498A1 AR P980104605 A ARP980104605 A AR P980104605A AR P980104605 A ARP980104605 A AR P980104605A AR 013498 A1 AR013498 A1 AR 013498A1
- Authority
- AR
- Argentina
- Prior art keywords
- alpha
- ifn
- amantadine
- chronic hepatitis
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
La presente invencion provee el uso de IFN-alfa en asociacion con amantadine para la manufactura de medicamentos para el tratamiento deinfecciones cronicas de hepatitis C. La presente invencion provee también medicamentos que contienen IFN-alfa y amantadine como una preparacioncombinada para uso simultáneo, separado o secuencial en terapia de infecciones cronicas de hepatitis C. La presente invencion provee además un método paratratar infecciones cronicas de hepatitis C en pacientes que necesitan dicho tratamiento que comprende administrar una cantidad de IFN-alfa en asociacioncon una cantidad de amantadine que es eficaz para tratar la hepatitis C.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97116220 | 1997-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR013498A1 true AR013498A1 (es) | 2000-12-27 |
Family
ID=8227366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980104605A AR013498A1 (es) | 1997-09-18 | 1998-09-16 | Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa |
Country Status (12)
Country | Link |
---|---|
US (1) | US20030031647A1 (es) |
EP (1) | EP1011714A2 (es) |
JP (1) | JP2001516725A (es) |
KR (1) | KR100364938B1 (es) |
CN (1) | CN1276730A (es) |
AR (1) | AR013498A1 (es) |
AU (1) | AU746648B2 (es) |
BR (1) | BR9812466A (es) |
CA (1) | CA2302834A1 (es) |
TR (1) | TR200000728T2 (es) |
WO (1) | WO1999013894A2 (es) |
ZA (1) | ZA988519B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080279819A1 (en) * | 2005-02-15 | 2008-11-13 | Adamas Pharmaceuticals, Inc. | Combinations Therapy for Treatment of Demyelinating Conditions |
WO2008011165A2 (en) | 2006-07-21 | 2008-01-24 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom |
WO2010014258A2 (en) * | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugates having a releasable linkage |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
AU5157998A (en) * | 1996-11-01 | 1998-05-29 | Thomas Najarian | Methods and compositions for treatment of hepatitis c infection |
US5849800A (en) * | 1997-03-28 | 1998-12-15 | The Penn State Research Foundation | Use of amantadine for treatment of Hepatitis C |
-
1998
- 1998-09-11 AU AU97430/98A patent/AU746648B2/en not_active Ceased
- 1998-09-11 BR BR9812466-8A patent/BR9812466A/pt not_active IP Right Cessation
- 1998-09-11 CN CN98809223A patent/CN1276730A/zh active Pending
- 1998-09-11 JP JP2000511513A patent/JP2001516725A/ja active Pending
- 1998-09-11 CA CA002302834A patent/CA2302834A1/en not_active Abandoned
- 1998-09-11 TR TR2000/00728T patent/TR200000728T2/xx unknown
- 1998-09-11 KR KR1020007002782A patent/KR100364938B1/ko not_active IP Right Cessation
- 1998-09-11 WO PCT/EP1998/005797 patent/WO1999013894A2/en not_active Application Discontinuation
- 1998-09-11 EP EP98951382A patent/EP1011714A2/en not_active Withdrawn
- 1998-09-16 AR ARP980104605A patent/AR013498A1/es not_active Application Discontinuation
- 1998-09-17 ZA ZA988519A patent/ZA988519B/xx unknown
-
2002
- 2002-09-06 US US10/236,268 patent/US20030031647A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA988519B (en) | 1999-03-18 |
KR100364938B1 (ko) | 2002-12-18 |
KR20010024044A (ko) | 2001-03-26 |
WO1999013894A3 (en) | 1999-06-03 |
US20030031647A1 (en) | 2003-02-13 |
AU746648B2 (en) | 2002-05-02 |
BR9812466A (pt) | 2000-09-19 |
WO1999013894A2 (en) | 1999-03-25 |
CA2302834A1 (en) | 1999-03-25 |
JP2001516725A (ja) | 2001-10-02 |
TR200000728T2 (tr) | 2000-09-21 |
EP1011714A2 (en) | 2000-06-28 |
CN1276730A (zh) | 2000-12-13 |
AU9743098A (en) | 1999-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2162393T3 (es) | Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica. | |
BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
ES2160707T3 (es) | Composiciones que comprenden agentes deteriorantes del adn y p53. | |
DE69434121D1 (de) | Pharmazeutische zusammensetzung zur immunstimulierenden therapie | |
DK0776202T3 (da) | Liposomalt indkapslet taxol, dets fremstilling af dets anvendelse | |
BRPI0518250A2 (pt) | tratamentos anticÂncer | |
NO20032027L (no) | Effektive antitumorbehandlinger | |
EE200200565A (et) | Vaskulaarse kahjustava toimega kombinatsioonravi | |
BR9814419A (pt) | "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" | |
UY26171A1 (es) | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía | |
UY24063A1 (es) | Empleo de concentrados con contenido de factor von willebrand (vwf) como terapia de combinacion en la terapia con antitromboticos y fibrinoliticos | |
AR013498A1 (es) | Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa | |
BR0307022A (pt) | Método de tratamento de um paciente que precisa de analgesia | |
CY1106388T1 (el) | Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη | |
AR007059A1 (es) | Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto | |
ES2168772T3 (es) | Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina. | |
BR0211323A (pt) | Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina | |
BR9708037A (pt) | Método para o tratamento de abuso de substância | |
WO2004064855A8 (de) | Medikament und verwendung zur tumortherapie | |
DK1150981T3 (da) | Terapeutisk necleosidforbindelse | |
ECSP993003A (es) | Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica | |
PT1313500E (pt) | Associacoes de dalfopristina/quinupristina com o cefpirome | |
DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon | |
EA199800820A1 (ru) | Способ лечения злоупотребления лекарственными средствами | |
UA40393A (uk) | Спосіб лікування хронічного обструктивного бронхіту |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |